Rep profile
Rep profile
Murrell Bollinger
company
3M Pharmaceuticals
Title
Professional sales representative
current home
Winchester, VA
Territory: Shenandoah Valley region.
Customers: OB/GYNs, cardiologists, primary care physicians and internal medicine.
Awards: Bronze and silver awards; Sales rep of the year 1994, 1995 and 1996; Honors Circle member.
Sales techniques: "I find a common interest between the physician and myself. This separates me from other reps and makes the physicians more receptive to me. I don't try to get the physician to write a lot of prescriptions at once. I am confident in the products I sell and believe that if I can get the physician to write at least one prescription, he or she will want to use the product again."
Sales Philosophy: "I believe a rep needs to be honest to earn the respect of a physician."
Motivation: "I have a strong desire to compete and to win. I don't get discouraged. If someone tells me something is too difficult or can't be done, that gives me incentive to try even harder."
Interest in industry: "After I graduated from college, a friend who was a pharmacist told me about pharmaceutical sales. I talked with someone in the field and knew that I had found my niche."
Industry change: "The pharmaceutical industry has changed a lot. Reps today must be technically oriented. They must stay on top of changes and new processes in the pharmaceutical industry. There are also more specialists today. Representatives need to keep on top of research in order to sell to physicians who concentrate in one area of medicine."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.